Novartis (Basel, Switzerland) have announced positive results from the 6-month Phase III STRIVE study evaluating erenumab for the prevention of episodic migraine, reporting that 50% of patients taking the drug had their number of migraine days cut by at least half. In addition, Teva Pharmaceuticals (Jerusalem, Israel) have published data from the Phase III HALO study for another monoclonal antibody, fremanezumab, for chronic migraine, showing that 41% of treated patients halved their number of migraine days.
Restricted Content / Members Only
You cannot view this content because It is available to members only. Please Login or Register to view this area.